SureTrader Nadex Advertisement PGUS
Home > Boards > US OTC > Cannabis >

ProText Mobility, Inc. (TXTM)

TXTM RSS Feed
Add TXTM Price Alert      Hide Sticky   Hide Intro
Moderator: kimokahu, brucebill, OneBrokeMama, F.STOTLER, Dr_Q, Dakotarrb
Search This Board: 
Last Post: 3/23/2017 5:42:18 PM - Followers: 490 - Board type: Free - Posts Today: 64






PROTEXT MOBILITY, INC.

Stock Symbol: TXTM

http://www.protextm.co


http://plandaibiotech.com

https://twitter.com/protxtm
 
 

On December 31, 2016, we completed a share exchange with Plandaí Biotechnology South Africa (Pty) Ltd. in which we acquired 100% of the outstanding stock of Plandaí. As a result of this transaction, the shareholders of Plandaí became the majority owners of Protext Mobility and Plandaí elected to become the “successor issuer” for SEC reporting purposes.

Plandaí is a research company headquartered in the Mpumalanga province of South Africa, approximately an hour west of the Kruger National Park in the northeast part of the country. Plandaí has the worldwide exclusive license to develop and market pharmaceutical applications for Phytofare® extracts, including the green-tea derived Catechin Complex that has been clinical proven to be 10-times more bioavailable than generics.

Green tea catechins have demonstrated a wealth of clinical health benefits and can be found in many different nutraceutical products, especially for weight loss. In laboratory, in vitro studies, catechins have shown remarkable potential for treating viruses, bacterial infections, inflammation, preventing certain cancers, and regulating blood sugar levels. However, like many botanical extracts, green tea has notoriously low bioavailability. Meaning, very little of what is consumed makes it intact to the blood stream. Phytofare®, with its superior bioavailability, can deliver all 8 catechins to the blood stream at therapeutic levels, where they remain active for over 24 hours.

What this means is that we have the potential, for the first time, to use an all-natural extract for pharmaceutical applications.

Commencing in early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in controlling blood sugar levels in diabetics. Mauritius has the highest per-capita incidence levels of diabetes in the world. Assuming the trials results are favorable, we anticipate having a product market-ready by Q4 2017 specific for managing insulin.

Future clinical trials will involve both the Catechin Complex and a citrus-based Limonoid Complex as we pursue treatments for inflammation, viruses (including malaria), soft-tissue injuries, and capillary integrity.


 

Plandai Biotechnology South Africa (pty) Ltd, recently acquired by Protext Mobility, Inc, is publicly traded on the OTC Markets under the ticker symbol "TXTM"

The Company is actively engaged in the research and clinical testing of “bioceutical” products—all natural ingredients formulated for pharmaceutical applications and processed under pharma-grade conditions. Our initial product, Phytofare® Catechin Complex, has been clinically proven to have 10 times greater bioavailability over generic catechin extracts. Commencing early 2017, we will be conducting a human clinical trial to determine the effectiveness of Phytofare® in regulating blood sugar levels in diabetics. The trial will be conducted in the island country of Mauritius which has the highest per capita incidence of diabetes in the world. Assuming a favorable result, we anticipate having a product market ready by the end of 2017 and eventually filing for product claims with the US Food and Drug Administration.

We are majority-owned by Plandaí Biotechnology, Inc. (OTCQB: PLPL), a London-based holding company that controls over 8,000 acres of tea estate in the province of Mpumalanga, South Africa, and owns a 100,000 square foot manufacturing facility that produces Phytofare®.









PROTEXT MOBILITY CLOSES ACQUISTION OF PLANDAI BIOTECHNOLOGY WHOLLY OWNED SUBSIDIARY (PLPL-SA) Boca Raton, FL – January 11th, 2016 - Protext Mobility Inc. (OTCPINK: TXTM) announced that it has completed the acquisition of Plandaí Biotechnology South Africa (PTY) LTD “Plandaí SA”, a wholly owned subsidiary of Plandaí Biotechnology, Inc., publicly traded under the ticker (PLPL). Plandaí SA is a biotechnology firm engaged in the research and development of botanical extracts, such as green tea, aimed at treating metabolic disorders, including diabetes. The parent company of Plandaí SA, Plandaí Biotechnology, Inc., is the culmination of over 10 years of research and development in the field of plant extracts with principle holdings including raw materials processing, infrastructure, production facilities, farms and land totaling 7500 acres in the province of Mpumalanga, South Africa. Plandaí SA was established in 2014 by parent company, Plandaí Biotechnology, Inc. to provide a platform for expanding the research of Plandaí’s proprietary Phytofare® extracts into pharmaceutical applications. Phytofare® has been clinically proven in studies to provide ten times greater bioavailability, which is the ability of the body to absorb the nutrients, over generic plant extracts. The first product brought to market, Phytofare® catechin complex, is derived from green tea and contains all eight catechins in a highly absorbable biocompatible structure. Where the parent company, Plandaí Biotechnology, focuses on selling Phytofare® as an ingredient to manufacturers in the nutraceutical industry, Plandaí SA will target the pharmaceutical market with a finished product. Plandaí SA has the exclusive license and rights to develop, manufacture, and sell all current and future Phytofare® extracts for the pharmaceutical market worldwide. The first targeted product will focus on treating diabetes by regulating blood sugar levels with an expectation of being market ready in the latter half of 2017. David Lewis, Director of Protext Mobility, commented, “We’re pleased to announce this share exchange with Plandaí SA and we’re confident that this transaction will create exciting new opportunities for the company. Plandaí has a proven track record for delivering high-quality, science-based botanical ingredients that fit perfectly into the bio-pharmaceutical space. With the first human clinical trial set to commence in the first quarter of 2017, we anticipate great things in the coming months.” The Company is also pleased to announce the appointment of Mr. Roger Duffield to the role of Chief Executive Officer and Chairman of the Board. Mr Duffield is a seasoned executive, responsible for the massive undertaking and successful development of the 7500 acre Senteeko Estate. Mr.Duffield, is a hands on CEO, currently in South Africa, overseeing the 100,000 square foot factory, and preparing for the upcoming human clinical trial being conducted by Plandai SA. 
 

Plandai Biotechnology South Africa

Plandaí Biotechnology South Africa (Pty) Ltd, recently acquired by Protext Mobility, Inc.(OTCPINK: TXTM) is a South Africa-based research company focusing on the development of pharmaceutical applications for botanical drugs.

Plandaí South Africa has the worldwide exclusive license to develop Phytofare® in botanical drug applications. Phytofare® is a highly bioavailable extract produced from live green tea leaves that has been clinically proven in double-blind human trials to have ten-times greater bioavailability over generic extract. What this means is that Phytofare® can deliver a therapeutic level of catechins to the system where they remain active for over 24 hours. The Company plans to commence human clinical trials to determine the effectiveness of using Phytofare® catechin complex in regulating insulin levels in Type II Diabetes patients.

Diabetes is now the leading cause of death in South Africa and the rates are only climbing through much of sub-Sahara Africa and the developing world where fat-rich foods have supplanted traditional diets. There is a strong body of scientific research that points to the effectiveness of green tea catechins in managing obesity, high blood pressure, diabetes and other diet-related diseases. Data from in vitro and in vivo studies suggest that green tea catechins, in particularly EGCG, exert anti-obesity effects via several mechanisms including inhibition of adipocyte differentiation and proliferation, reduction of fat absorption, and the reduction in fat mass, tricylglycerides, free fatty acids and total cholesterol. The majority of human intervention studies investigating glucose homeostasis further demonstrate improved glucose levels in response to green tea catechins. Human studies have shown anti-obesity, anti-diabetic and cardio-protective effects of green tea catechins (1).

However, as we all know, like many botanical ingredients green tea is poorly absorbed into the blood stream, rendering it an ineffective primary control therapy. Phytofare®, on the other hand, which has ten-times greater absorption, may very well provide an inexpensive, all-natural solution to these diseases. Our clinical trial is designed to build on this prior research and show the benefits of Phytofare® in managing glucose levels, with a short-term goal of having a consumer-ready capsule product by Q4, 2017.

Worldwide as of 2015, 415 million people had diabetes, with the number growing to over 642 million people in 2016, with Type II Diabetes making up about 90% of the cases. In 2014, the IDF estimated that diabetes resulted in 4.9 million annual deaths.

1. F. Thielecke, M. Boschmann / Phytochemistry (2009) “The potential role of green tea catechins in the prevention of the metabolic syndrome” ?
 

Roger Duffield - President & CEO

Roger Duffield has a significant background in the development and management of start-ups, private and public companies, especially in the United States, Europe and South Africa. His previous contributions in the United States public sector include Klinair Technologies Inc. and Rhombic Inc. relating to energy and hydrocarbon technologies. Through his extensive involvement with research and development programs with a number of academic institutions, including Penn State, University of Southern California, University of Washington, and the University of Limerick, Ireland, he was awarded two honorary Russian doctorates in Natural Sciences from the University of Moscow and Novosibirsk. In 2001 the Foundation for International Services, California recognized a degree in BSc. Chemical Engineering.

In 2001 he co-founded Global Energy Solutions Corporation Limited, Dublin, Ireland, recently acquired by Plandaí Biotechnology, Inc., and in 2003, the USA-based Research Company, CRS Technologies Inc. Mr. Duffield now heads this group of companies specializing, through private and public investment in the farming and recovery of highly valuable botanical extracts with unique characteristics.'


Contact Details

9 Palm Street
White River 1240
Mpumalanga
South Africa

 P: +1 (435) 881 3611
 E: [email protected]

  •  
     
RESURRECTED FROM A LONG REST!
 
 

 


 

 

American Stock Transfer & Trust Company
Transfer Agent
6201 15th Avenue
Brooklyn, NY 11219
800-937-5449
http://www.amstock.com
 


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TXTM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
TXTM News: Halitron, Inc. (OTC Pink: HAON) – To Complete Merger, Issue Stock Dividend and Up List with $5 Million Revenue Target 02/27/2017 07:00:00 AM
TXTM News: USMJ PPS Holds Up Against Short Selling – Short Squeeze Potential To Push Past $0.0017 Resistance 02/03/2017 09:38:17 AM
TXTM News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 01/27/2017 10:34:38 AM
TXTM News: Securities Registration (section 12(g)) (8-a12g) 01/27/2017 10:29:43 AM
TXTM News: Current Report Filing (8-k) 01/19/2017 11:32:53 AM
PostSubject
#31457  Sticky Note **NEWS** Protext Mobility Discusses Potential Effectiveness of Phytofare retiredtech 03/07/17 10:22:21 AM
#31422  Sticky Note $$TXTM Protext Mobility Discusses Potential Effectiveness of Phytofare BigBadWolf 03/07/17 09:39:05 AM
#30885  Sticky Note LDvita- Mega DD--$TXTM /PlandaiSA Domination over MMJ in S.Africa DD_dempsey 03/05/17 04:12:26 AM
#12849  Sticky Note Protext Mobility Inc (TXTM) Launches New Website and Carjockey2 12/12/16 02:18:20 PM
#33903   Oversold and bollis are tight!!!! fly_fisherman 03/23/17 06:07:02 PM
#33902   O.K. Nitwit 03/23/17 05:42:18 PM
#33901   Last time we had news on a Friday... La Dolce Vita 03/23/17 05:17:14 PM
#33900   StoptheInsanity9, You said that @ .0001 no bid :-) Nitwit 03/23/17 05:15:05 PM
#33899   Makes you wonder about a company that can StoptheInsanity9 03/23/17 05:14:34 PM
#33898   Anything is possible ;-) Nitwit 03/23/17 05:14:21 PM
#33897   Cause there nothing trust me been here since Going2Pot 03/23/17 04:57:05 PM
#33896   What is improper about the present time? There altitudy 03/23/17 04:51:51 PM
#33895   Got me another mil today at .0015 jxcxjx03 03/23/17 04:20:43 PM
#33894   GETTING CLOSE..... fly_fisherman 03/23/17 03:57:03 PM
#33893   Yeaaa !!!! Up we go CrazyKar123 03/23/17 03:52:43 PM
#33892   That's your assessment, we shall see. IPDF 03/23/17 03:52:33 PM
#33891   $TXTM News on Friday Possible.. La Dolce Vita 03/23/17 03:52:27 PM
#33890   It already took off. That ship sailed. This StoptheInsanity9 03/23/17 03:51:32 PM
#33889   Can't wait for this to take off. IPDF 03/23/17 03:48:35 PM
#33888   Bet you 100 it doesn't go to .001 dsoulliere 03/23/17 03:44:35 PM
#33887   001 tomorrow? Got my order in! Rymar3 03/23/17 03:41:59 PM
#33886   Most recent $TXTM tweet: trading.jeff 03/23/17 03:35:47 PM
#33885   That twitter feed is lame. Amazing how people StoptheInsanity9 03/23/17 03:35:37 PM
#33884   Check Twitter! They just said something positive Frozenbravo 03/23/17 03:27:54 PM
#33883   Guess someone wants back in. Or he's bipolar dsoulliere 03/23/17 03:18:51 PM
#33882   All good green tea makes you poop...It is La Dolce Vita 03/23/17 03:08:49 PM
#33881   Massive dumps. Phytofare makes you poop yourself. Scam. Habitant99 03/23/17 03:06:34 PM
#33880   wow big bid and oversold, might take a ttrader707 03/23/17 03:02:05 PM
#33879   Becoming oversold folks...... fly_fisherman 03/23/17 03:00:53 PM
#33878   Im still waiting to get my shares umder stockpicker1 03/23/17 02:57:20 PM
#33877   Like to see the 15teens for one last CrazyKar123 03/23/17 02:51:17 PM
#33876   Fyi- it's for all intents and purposes Frozenbravo 03/23/17 02:14:47 PM
#33875   From what I read..... fly_fisherman 03/23/17 02:11:56 PM
#33874   I'm ready for this to fly....enough of these elevate333 03/23/17 01:56:22 PM
#33873   $TXTM .0018 tapped, HOD. trading.jeff 03/23/17 01:54:49 PM
#33872   Some nice little action right now. Bid building dsoulliere 03/23/17 01:54:12 PM
#33871   $TXTM A few nice slaps at .0017. trading.jeff 03/23/17 01:45:55 PM
#33870   There is medicine for that dangbro 03/23/17 01:33:22 PM
#33869   and this turd continues to somehow manage to float. larhop 03/23/17 01:29:09 PM
#33868   Added more myself this morning dangbro 03/23/17 01:26:05 PM
#33867   Added more this morning..... fly_fisherman 03/23/17 01:23:59 PM
#33866   nice i_like_bb_stock 03/23/17 01:11:48 PM
#33865   agree bb picked up some today MOMO 03/23/17 01:05:05 PM
#33864   Nice pick-up. Im trying for 1.5 million at stockpicker1 03/23/17 12:34:44 PM
#33863   Picked up a partial fill 350K @.0014 this soul2soul 03/23/17 12:18:20 PM
#33862   Just checking in what happened to the merger? mddmsimpson 03/23/17 12:11:40 PM
#33861   IGD(instant gratification disease)....So true! Lol Kramden1 03/23/17 11:58:27 AM
#33860   Most of you know this stock is doing moetser 03/23/17 11:52:11 AM
#33859   A few more days of SA MM review! josemaria 03/23/17 11:49:16 AM
#33858   Just can't get any under 0015. Still waiting stockpicker1 03/23/17 10:59:18 AM
#33857   Good for you...but you may want to get La Dolce Vita 03/23/17 10:56:43 AM
#33856   Good luck with that! ComeWhatMay 03/23/17 10:53:58 AM
#33855   i'm already out, buying back in at 001. Rymar3 03/23/17 10:52:51 AM
#33854   Agreed, "we will get going very soon". La Dolce Vita 03/23/17 10:47:57 AM
PostSubject